Surgery Websites
Surgical Oncology Program »  Meet the Team »  Surgical Oncology »  Amrita Basu, PhD
Amrita Basu, Ph.D

Amrita Basu, Ph.D

  • Assistant Professor of Surgery
  • Division of Surgical Oncology

Contact Information

550 16th. Street, #6351
San Francisco, CA 94158
Open Popup
  Dept or School    
  End Date    
  • Broad Institute of Harvard and MIT, Cambridge, MA
  • Postdoctoral Fellow
  • Computational Chemical Biology
  • Rockefeller University, Tri-Institutional Computational Biology Program, New York, New York
  • Ph.D.
  • Computational Biology
  • Cornell University, Ithaca. NY
  • B.S.
  • Electrical Engineering
  • Development of computational models for early detection of cancer lesions and progression to metastatic disease can help discriminate between high and low cancer risk profiles. Therefore, we seek to exploit diverse, high-throughput genomic and clinical data to understand the molecular networks underlying fundamental cellular processes that can eventually stratify patients by non-traditional underpinnings, including transcriptional regulation, epigenetic signaling, and chemosensitivity. Our algorithmic methods draw on machine learning, a computational field concerned with learning accurate, predictive models from noisy and high-dimensional data.

    Another area of research includes developing standardized methods and measures to integrate drug toxicity, quality of life, and efficacy measures for breast cancer patients. We are building infrastructure and tools to support patient-reported outcomes collection and downstream analysis and visualization.
      Confired By    
  • Burroughs Wellcome Fund Innovation in Regulatory Science Award
  • 2021 - 2026
  • Interstellar Award (New York Academy of Sciences/Japan Center for Medical Research and Development)
  • 2019 - 2020
  • White House Presidential Innovation Fellow
  • 2016 - 2017
  • Sage Bionetworks Young Investigator Award
  • 2013
  • Data provided by UCSF Profiles, powered by CTSI
    • Analyzing Patient-level Data in a Breast Cancer Clinical Trial
      Sponsor ID:
      Funding Period:
      Jul 2023
      Jul 2028
      Principal Investigator
    • Developing a Toxicity Framework using Patient-Reported Outcome
      Sponsor ID:
      Funding Period:
      Sep 2021
      Sep 2026
      Principal Investigator
    • Predicting the Likelihood of Immune-related Adverse Events in Breast Cancer Patients
      Sponsor ID:
      Funding Period:
      Jan 0001
      Jan 0001
      Principal Investigator
    Data provided by UCSF Profiles, powered by CTSI
    1. Umashankar S, Basu A, Esserman L, Van't Veer L, Melisko ME. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients. Cancer Med. 2023 Oct 30. View in PubMed
    2. Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer. Breast Cancer Res. 2023 Oct 04; 25(1):117. View in PubMed
    3. Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes. Front Oncol. 2023; 13:1192208. View in PubMed
    4. Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Res Treat. 2023 Apr; 198(2):383-390. View in PubMed
    5. Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort. Cancer Res Commun. 2022 12; 2(12):1579-1589. View in PubMed
    6. View All Publications


    Site Directory